Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 45

1.

Aptamers: Promising Tools for Cancer Diagnosis and Therapy.

Cerchia L.

Cancers (Basel). 2018 May 3;10(5). pii: E132. doi: 10.3390/cancers10050132.

2.

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB.

Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E.

Oncotarget. 2018 Apr 13;9(28):19929-19944. doi: 10.18632/oncotarget.24961. eCollection 2018 Apr 13.

3.

Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.

Monaco M, Palma G, Vitiello M, Capiluongo A, D'Andrea B, Vuttariello E, Luciano A, Cerchia L, Chiappetta G, Arra C, Fusco A, Fedele M.

Cancers (Basel). 2018 Mar 27;10(4). pii: E92. doi: 10.3390/cancers10040092.

4.

Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.

Camorani S, Crescenzi E, Fedele M, Cerchia L.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21. Review.

PMID:
29574128
5.

The POZ/BTB and AT-Hook Containing Zinc Finger 1 (PATZ1) Transcription Regulator: Physiological Functions and Disease Involvement.

Fedele M, Crescenzi E, Cerchia L.

Int J Mol Sci. 2017 Nov 24;18(12). pii: E2524. doi: 10.3390/ijms18122524. Review.

6.

The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.

Fedele M, Cerchia L, Chiappetta G.

Cancers (Basel). 2017 Sep 30;9(10). pii: E134. doi: 10.3390/cancers9100134. Review.

7.

PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.

Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, Arra C, Crescenzi E, Cerchia L, De Caro MLDB, Fedele M.

Oncotarget. 2017 Jul 25;8(35):59282-59300. doi: 10.18632/oncotarget.19546. eCollection 2017 Aug 29.

8.

Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.

Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A.

Theranostics. 2017 Aug 22;7(14):3595-3607. doi: 10.7150/thno.18974. eCollection 2017.

9.

Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.

Monaco I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A, Niclou S, Arra C, Chiariello M, Cerchia L, Comes Franchini M.

J Med Chem. 2017 May 25;60(10):4510-4516. doi: 10.1021/acs.jmedchem.7b00527. Epub 2017 May 10.

PMID:
28471660
10.

Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L.

Sci Rep. 2017 Apr 20;7:46659. doi: 10.1038/srep46659.

11.

PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.

Franco R, Scognamiglio G, Valentino E, Vitiello M, Luciano A, Palma G, Arra C, La Mantia E, Panico L, Tenneriello V, Pinto A, Frigeri F, Capobianco G, Botti G, Cerchia L, De Chiara A, Fedele M.

Oncotarget. 2016 Sep 13;7(37):59158-59172. doi: 10.18632/oncotarget.10993.

12.

PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells.

Vitiello M, Valentino T, De Menna M, Crescenzi E, Francesca P, Rea D, Arra C, Fusco A, De Vita G, Cerchia L, Fedele M.

Sci Rep. 2016 Apr 29;6:25268. doi: 10.1038/srep25268.

13.

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ieranò C, Cerchia L, Lucarelli E, Scala S, Zannetti A.

Cancer Lett. 2016 Jan 1;370(1):100-7. doi: 10.1016/j.canlet.2015.10.018. Epub 2015 Oct 27.

PMID:
26517945
14.

Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.

Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.

Oncotarget. 2015 Nov 10;6(35):37570-87. doi: 10.18632/oncotarget.6066.

15.

Oligonucleotide aptamers for glioma targeting: an update.

Camorani S, Cerchia L.

Cent Nerv Syst Agents Med Chem. 2015;15(2):126-37.

PMID:
25924917
16.

Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer.

Camorani S, Esposito CL, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V, Cerchia L.

Mol Ther. 2014 Apr;22(4):828-41. doi: 10.1038/mt.2013.300. Epub 2014 Jan 2.

17.

Multifunctional aptamer-miRNA conjugates for targeted cancer therapy.

Esposito CL, Cerchia L, Catuogno S, De Vita G, Dassie JP, Santamaria G, Swiderski P, Condorelli G, Giangrande PH, de Franciscis V.

Mol Ther. 2014 Jun;22(6):1151-1163. doi: 10.1038/mt.2014.5. Epub 2014 Jan 20.

18.

The isolectin IB4 binds RET receptor tyrosine kinase in microglia.

Boscia F, Esposito CL, Casamassa A, de Franciscis V, Annunziato L, Cerchia L.

J Neurochem. 2013 Aug;126(4):428-36. doi: 10.1111/jnc.12209. Epub 2013 Mar 17.

19.

Signal transduction alterations in glioma: implications for diagnosis and therapy.

Cerchia L, Martinez Montero JC, Monfared P.

J Signal Transduct. 2012;2012:704247. doi: 10.1155/2012/704247. Epub 2012 Dec 9. No abstract available.

20.

Electrochemical detection of miRNA-222 by use of a magnetic bead-based bioassay.

Bettazzi F, Hamid-Asl E, Esposito CL, Quintavalle C, Formisano N, Laschi S, Catuogno S, Iaboni M, Marrazza G, Mascini M, Cerchia L, De Franciscis V, Condorelli G, Palchetti I.

Anal Bioanal Chem. 2013 Jan;405(2-3):1025-34. doi: 10.1007/s00216-012-6476-7. Epub 2012 Oct 26.

PMID:
23099529

Supplemental Content

Loading ...
Support Center